Evidence map›Paper›PMID 39765340›Full record

ArticleInternational neurourology journal2024

Implantable Neuromodulation for Neurogenic Lower Urinary Tract Dysfunction: A Single-Institution Retrospective Study.

Karis Buford, Haley Eisner, Annah Vollstedt, Brett Friedman, Jason Gilleran, Bernadette M M Zwaans, Kenneth M Peters, Priya Padmanabhan

Abstract read
In one paragraph

Article in International neurourology journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Innovation and the Importance of Patient-Centered Treatment.International neurourology journal · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Karis BufordCorewell Health William Beaumont University Hospital, Royal Oak, MI, USA.
Haley EisnerCorewell Health William Beaumont University Hospital, Royal Oak, MI, USA.
Annah VollstedtUniversity of Iowa, Iowa City, IA, USA.
Brett FriedmanOakland University William Beaumont School of Medicine, Rochester, MI, USA.
Jason GilleranCorewell Health William Beaumont University Hospital, Royal Oak, MI, USA.
Bernadette M M ZwaansCorewell Health William Beaumont University Hospital, Royal Oak, MI, USA.
Kenneth M PetersCorewell Health William Beaumont University Hospital, Royal Oak, MI, USA.
Priya PadmanabhanCorewell Health William Beaumont University Hospital, Royal Oak, MI, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeNeurogenic lower urinary tract dysfunction (NLUTD) is highly prevalent among patients with neurologic disorders. Some studies have demonstrated that implantable neuromodulation can improve symptoms of NLUTD. We seek to describe our experience with sacral and pudendal neuromodulation in patients with NLUTD.

methodsA retrospective chart review of patients with "neurogenic bladder" ICD-9/10 (International Classification of Diseases, Ninth Revision/10th Revision) code was performed at a single institution. This included patients from 2008 to 2020 who underwent stage 1 neuromodulation trial. Demographic and clinical information was collected, including neurologic diagnosis, the character of patients' voiding symptoms, the presence or absence of fecal incontinence, the need for intermittent catheterization, and whether patients had sufficient (>50%) improvement in their symptoms to undergo stage 2 implantable pulse generator (IPG) placement.

resultsWe identified 82 patients with neurologic diagnoses who underwent stage 1 neuromodulation. The most common diagnoses were diabetic cystopathy (17.07%), spinal surgery (17.07%), and spinal cord injury (12.20%). The most commonly reported symptoms were urinary urgency, and urge urinary incontinence. Overall, 59 patients (71.95%) advanced to stage 2 IPG placement including 72% of patients with sacral leads and 76% with pudendal leads.

conclusionNeuromodulation is feasible and effective in the treatment of NLUTD. Further investigation into its utilization is warranted.

Indexed as

Neurogenic bladderNeurogenic lower urinary tract dysfunctionNeuromodulationSpina bifida

Identifiers

PMID39765340
PMCPMC11710956

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.